Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KRONOS BIO, INC.

(KRON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kronos Bio Announces Participation in Upcoming Investor Conferences

11/24/2021 | 07:01am EST

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:

  • Piper Sandler’s 33rd Annual Virtual Healthcare Conference on Tuesday, November 30, 2021 at 11 a.m. Eastern Time; and
  • Evercore ISI’s 4th Annual HealthCONx on Thursday, December 2, 2021 at 1 p.m. Eastern Time.

The fireside chats will be available on the Investors & Media section of the company’s website at www.kronosbio.com. A replay of the webcasts will be archived and available for one month following each event.

About Kronos Bio, Inc.

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

Company contact:
Marni Kottle
Kronos Bio
650-900-3450
mkottle@kronosbio.com

Investors:
Claudia Styslinger
Argot Partners
212-600-1902
kronosbio@argotpartners.com

Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com


Primary Logo

Source: Kronos Bio, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about KRONOS BIO, INC.
01/14INSIDER BUY : Allogene Therapeutics
MT
2021KRONOS BIO, INC.(NASDAQGS : KRON) added to NASDAQ Biotechnology Index
CI
2021KRONOS BIO, INC.(NASDAQGS : KRON) added to S&P Biotechnology Select Industry Index
CI
2021Kronos Bio Says First Patient Dosed in Trial of Leukemia Treatment Entospletinib
MT
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entosplet..
GL
2021Kronos Bio, Inc. Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Ent..
CI
2021Kronos Bio's Cancer Drug Candidate Shows Potential in Phase 1/2 Trial
MT
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor ..
GL
More news
Analyst Recommendations on KRONOS BIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -144 M - -
Net cash 2021 178 M - -
P/E ratio 2021 -3,30x
Yield 2021 -
Capitalization 505 M 505 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 95
Free-Float 83,1%
Chart KRONOS BIO, INC.
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | KRON | US50107A1043 | MarketScreener
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 8,96 $
Average target price 40,25 $
Spread / Average Target 349%
EPS Revisions
Managers and Directors
Norbert W. Bischofberger President, Chief Executive Officer & Director
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Arie S. Belldegrun Chairman
Jorge DiMartino Chief Medical Officer & EVP-Clinical Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KRONOS BIO, INC.-34.07%505
MODERNA, INC.-37.21%64 657
LONZA GROUP AG-17.41%50 233
IQVIA HOLDINGS INC.-15.35%45 624
SEAGEN INC.-17.45%23 336
ICON PUBLIC LIMITED COMPANY-15.10%21 404